Viruses, Vol. 16, Pages 552: A Comparative Study of Human Pluripotent Stem Cell-Derived Macrophages in Modeling Viral Infections
In this study, we generated induced macrophages (iMACs) derived from human pluripotent stem cells (hPSCs) to investigate the interactions between the macrophages and various human pathogens, including the hepatitis C virus (HCV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Streptococcus pneumoniae. iMACs can engulf all three pathogens. A comparison of the RNA-seq data of the iMACs encountering these pathogens revealed that the pathogens activated distinct gene networks related to viral response and inflammation in iMACs. Interestingly, in the presence of both HCV and host cells, iMACs upregulated diff...
Source: Viruses - April 1, 2024 Category: Virology Authors: Yaxuan Zhang Hui Qiu Fuyu Duan Haoran An Huimin Qiao Xingwu Zhang Jingren Zhang Qiang Ding Jie Na Tags: Article Source Type: research
Genes, Vol. 15, Pages 448: Predictive Role of Cluster Bean (Cyamopsis tetragonoloba) Derived miRNAs in Human and Cattle Health
ishor Gaikwad
MicroRNAs (miRNAs) are small non-coding conserved molecules with lengths varying between 18-25nt. Plants miRNAs are very stable, and probably they might have been transferred across kingdoms via food intake. Such miRNAs are also called exogenous miRNAs, which regulate the gene expression in host organisms. The miRNAs present in the cluster bean, a drought tolerant legume crop having high commercial value, might have also played a regulatory role for the genes involved in nutrients synthesis or disease pathways in animals including humans due to dietary intake of plant parts of cluster beans. However, the ...
Source: Genes - April 1, 2024 Category: Genetics & Stem Cells Authors: Sarika Sahu Atmakuri Ramakrishna Rao Tanmaya Kumar Sahu Jaya Pandey Shivangi Varshney Archna Kumar Kishor Gaikwad Tags: Article Source Type: research
Racial and Ethnic Disparities in Transplantation of Lungs From HCV-Infected Donors into HCV-Negative Recipients
Purpose: Transplanting organs from hepatitis c virus (HCV) infected donors into HCV-negative recipients has led to thousands of more transplants in the US since 2016. Studies have demonstrated disparities in utilization of kidneys from these donors along the lines of gender and education. It is still unknown, however, if the same disparities are seen in lung transplantation. The goal of this study was to determine if there were disparities present in the usage of HCV infected donor lungs related to recipient demographics. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , D. Goldberg Source Type: research
Hepatitis C Infected Heart/Kidney Transplantation into HCV Uninfected Recipient Without Transmission
Introduction: Eighty million people worldwide live with chronic hepatitis C virus (HCV) infection. The ability to cure HCV with direct-acting antiviral agents (DAAs) has expanded the donor pool and continues to be studied by transplant programs globally. It has been well reported that nearly 100% of recipients transplanted with HCV nucleic acid amplification testing positive (NAT+) organs develop donor-derived HCV infection. The median time for detectable HCV NAT for uninfected renal transplant recipients who receive NAT+ grafts is post-transplant day three. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Tanna Source Type: research
Crossing the Turbulent Hepatitis Sea: Use of Prophylactic Glecaprevir/Pibrentasvir to Facilitate Cardiothoracic Transplants from Hepatitis C Viremic Donors in Australia
Purpose: The availability of direct acting antivirals has enabled the acceptance of cardiothoracic organs from hepatitis C (HCV) positive donors, and this has become commonplace in the US. Issues of cost and antiviral access have delayed implementation in Australia. We aim to evaluate the first use of compassionate access prophylactic glecaprevir/pibrentasvir to prevent HCV infection in cardiothoracic transplant recipients receiving organs from viraemic donors in a single Australian center. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , L. Carlos, B. Schnegg, D. Darley, G. Matthews, P. MacDonald Source Type: research
Efficacy of Lung Transplantation from Hepatitis C+ Donors
Purpose: Lung transplantation is an effective treatment for end-stage lung disease. The development of effective direct acting antiviral treatment (DAAT) for hepatitis C virus (HCV) has led to an expanded donor pool. The primary aim of this project is to investigate outcomes in lung transplant recipients with HCV+ donors compared with HCV- donors. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , E.E. Bashian, G. Gardner, M. Ambrosio, W. Julliard, V. Kasirajan, Z. Hashmi Source Type: research
Impact of Hepatitis C Viremic Lung Donors on Waitlist Time and Outcomes in High-Risk Recipients
Purpose: Despite the advent of direct acting antivirals (DAA), the Hepatitis C viremic (HCV+) donors remain an untapped pool. Furthermore, published studies to date have been limited to successful outcomes in low risk profile candidates. Here, we report a case series of lung transplantation (LTx) from HCV+ donors into a cohort that includes: 1) Critically ill patients with high allocation score (LAS/CAS) on ECMO and mechanical ventilation, 2) Highly sensitized patients, and 3) Patients at risk for malabsorption. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Chen, M. Brzezinski, J. Price, B. Trinh, T. Deuse, R. Florez, S. Hays, L. Leard, J. Golden, J. Singer, J. Kukreja Source Type: research
Long-Term Outcomes of HCV-Positive Heart Recipients Based on UNOS Registry
Purpose: The use of Hepatitis C (HCV) nucleic acid amplification test (NAT) positive donors increased the heart donor pool, reduced waitlist time and mortality among heart transplant (HT) candidates. Short-term post-HT outcomes in HCV NAT-positive heart recipients are comparable to HCV-negative heart recipients. However, the long-term outcomes remain unknown. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Nunez, B. Pisani, G. Bhat, H. Eisen Source Type: research
Any Switch Way: Cure of Donor-Derived HCV Infection after Changing DAA Therapy Due to Drug Interactions
Introduction: Transplant centers have increased utilization of organs from hepatitis C virus (HCV) nucleic acid amplification testing (NAT) positive donors in recent years due to organ shortage and efficacy of direct acting antivirals (DAAs). Increased utilization of DAAs in transplant recipients has highlighted key drug interactions with immunosuppressants used in transplant recipients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , T. Carcella, F. Bartlett, M. Lange, C. Harris, C. Perez Source Type: research
Impella 5.5 Assisted Combined Liver-Kidney Transplantation
We present a case of a patient with chronic hepatitis C cirrhosis and marginal cardiac function who underwent Impella 5.5 assisted liver-kidney transplantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: Y.A. He, , L. Chou, E.E. Suarez Source Type: research
Acute Hepatitis After Lung Transplant in a Recipient from Hep C Donor: The Chicken or the Egg Phenomenon?
We present a case of acute hepatitis after lung transplant from an HCV positive donor confounded by amiodarone toxicity. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J.P. Braat, A. Arjuna Source Type: research
Racial and Ethnic Disparities in Transplantation of Hearts from HCV-Infected Donors into HCV-Negative Recipients
Purpose: Transplanting organs from hepatitis c virus (HCV) infected donors into HCV-negative recipients has led to thousands of more transplants in the US since 2016. Studies have demonstrated disparities in utilization of kidneys from these donors along the lines of gender and education. It is still unknown, however, if the same disparities are seen in heart transplantation. The goal of this study was to determine if there were disparities present in the receipt of HCV infected donor hearts. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , D. Goldberg Source Type: research
Impact and Outcomes of Hepatitis C Viremic Donors (HCV-NAAT) on Donor-Derived Cell-Free DNA Levels and Gene-Expresion Profiling (GEP-Allomap) in Heart Transplant Recipients
Purpose: Scarcity of donor availability has led to increased rates of HCV viremic donors (NAAT+). We aimed to assess the impact of NAAT+ donors on dd-cfDNA and GEP results in Heart Transplantrecipients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Fernandez Valledor, D. Oren, A. Rahman, G. Rubinstein, S. Rahman, C. Lee, J. Baranowska, M. Regan, Y. Mehlman, D. Lotan, E.M. DeFilippis, K. Theodoropoulos, J. Fried, V. Topkara, D. Majure, P. Colombo, J. Raikhelkar, M. Yuzefpolskaya, K. Clerkin, F. Source Type: research
Intermediate Term Outcomes of CAV Screening in Heart Transplant Recipients from Hepatitis C Viremic Donors versus Non-Hepatitis C Donors
We report 5-year outcomes from routine annual CAV screening by intravascular ultrasound (IVUS) in HCV-viremic donors [nucleic amplification test: NAT (+)] vs non-viremic donors: NAT (-). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Birs, E. Adler, K. Hong, S. Aslam, N. Wettersten Source Type: research
Prophylaxis of Donor-Derived HCV Infection in Cardiothoracic Transplant Recipients with Short-Course DAA Therapy
Purpose: Acceptance of hepatitis C virus (HCV) viremic organs has increased access to cardiothoracic transplant. However, standard 8-12 week HCV treatment courses increase cost and treatment burden to transplant recipients with unknown long-term effects on the allograft. We aimed to prevent transmission of HCV from HCV-viremic donors to uninfected cardiothoracic transplant recipients with a peri-operative short course of direct acting antiviral (DAA). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Aslam Source Type: research
